Delivra Health and Its Brands Dream Water(R) and LivRelief(TM) Report Results for Third Quarter of Fiscal 2026

Delivra Health reported fiscal Q3 2026 results (three and nine months ended March 31, 2026) that reveal a stunning collapse. Quarterly net revenue of C$1.25 million fell roughly 60% year-over-year, while nine-month revenue of C$6.89 million was down 24%. Gross margin in the quarter plummeted to 25% (from 50% a year earlier), and adjusted EBITDA swung from –C$194k to –C$949k. The company attributes the miss to geopolitical conflict that closed the Strait of Hormuz, halting critical shipments to the Middle East — a market that had been a major driver of Dream Water USA sales. E‑commerce growth (Dream Water Canada +16%, LivRelief +60% in Q3) could not offset the collapse in brick-and-mortar and international channels. Management says it expects Middle East shipping to resume in Q4 and fiscal 2027, but the damage is done.

Earlier press releases had painted a picture of gradual improvement. FY2025 showed 8% revenue growth and a narrowing net loss. Q1 fiscal 2026 delivered positive adjusted EBITDA and the CEO guided to a relaunch of LivRelief Infused and new product launches in H2 2026. Q2 results slipped modestly but were described as “temporary timing variability.” The Q3 blow-up contradicts that narrative and exposes an extreme dependency on a single, unstable trade route.

This is a clear, adverse material event. The company has moved from nearly breaking even (C$56k positive adjusted EBITDA in Q1) to a quarterly C$949k EBITDA loss, with revenue evaporating by 60%. The cause — geopolitical turmoil — is outside management’s control and introduces an enduring risk that was not previously flagged. The investment thesis of a slow, steady turnaround is shattered. The prior growth talk now looks hollow, and the balance sheet, though not fully disclosed, almost certainly requires near‑term capital if losses continue. The stock had already collapsed from C$0.35 to C$0.12—0.15 before this release, so the market had already sensed trouble, but the magnitude of the miss still matters. A routine quarterly miss would be a 5–10% revenue decline; a 60% decline is an existential‑level shock for a micro‑cap consumer company.

Delivra Health Brands Inc. (TSXV: DHB) is a consumer health and wellness company built around two main brands: Dream Water® (a liquid sleep aid and gummies containing melatonin, GABA, and 5‑HTP) and LivRelief™ (topical pain relief creams, including a CBD‑infused line sold through licensed cannabis channels). The flagship project is the Dream Water franchise, sold in North America and exported to international markets, with a growing direct‑to‑consumer e‑commerce presence. The company has been pivoting to capital‑lite distribution, as with the Peak Processing licence for LivRelief Infused in Canada.